eleclazine

Ligand id: 8413

Name: eleclazine

Structure and Physico-chemical Properties

2D Structure
Calculated Physico-chemical Properties
Hydrogen bond acceptors 4
Hydrogen bond donors 0
Rotatable bonds 5
Topological polar surface area 64.55
Molecular weight 415.11
XLogP 4.87
No. Lipinski's rules broken 0

Molecular properties generated using the CDK

No information available.
Summary of Clinical Use
Eleclazine (under its research code GS-6615) is being evaluated in Phase III clincal trials as a potential treatment for long QT-3 (LQT3) syndrome and hypertrophic cardiomyopathy. Phase II trials for chronic stable angina and coronary artery disease, and ventricular arrhythmia are underway. In May 2015, the US FDA granted eleclazine (under its IUPAC name) orphan drug designation for the treatment of congenital long QT syndrome.